Umbilical Cord Blood Breakthroughs - Time for Cord Blood Stocks?

Cord blood is blood that comes from umbilical cords, and contains a significant amount of hematopoietic stem cells. Specialized cord blood banks are available to store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Parents often have their newborn's cord blood preserved in the event it may be needed at some point in the future for treatment of their child's or the child's sibling's cancer or genetic disease.

Numerous diseases have been treated with cord blood. As an example, several years ago, The Fred Hutchinson Cancer Center in Seattle, Washington made a major breakthrough in the use of umbilical cord blood to treat blood cancers such as leukemia. The discovery dramatically decreases the recovery time of white blood cells.

Even the U.S. House of Representatives recently passed a bill to extend the federal cord blood program. For additional information on cord blood and how it is collected, stored, and used, go to CordBloodStocks.com.

The cord blood industry is significant and continues to grow. Even Richard Branson, of Virgin Records and Virgin America (VA) fame, is in the cord blood business, setting up Virgin Health, a cord blood bank.

Investors can choose either the cord blood banks or the companies that use cord blood to develop cures. Here are some stocks that participate in the cord blood business. Be aware that some of these companies have low market caps and are very speculative.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a PE ratio of 9 and pays a yield of 1.3%.

PerkinElmer, Inc. (PKI) owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock has a PE of 34 and a yield of 0.6%.

Celgene (CELG) This New Jersey company is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The P/E is 47.6.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a PE of 20.4 and a yield of 2.1.

Cryo-Cell International (CCEL) This is a Florida based cord blood stem cell bank, specializing in the family market. The stock has a PE ratio of 92.

ThermoGenesis (KOOL) This California company designs, makes, and sells automated blood processing systems for the manufacture, preservation, and delivery of cell therapies. They are involved in a joint venture with GE Healthcare, a unit of General Electric Company (GE) to distribute the AXP[TM] AutoXpress Platform, a closed and automated system for harvesting mononuclear cells from cord blood. They have recently generated negative earnings.

Cord Blood America Inc. (CBAI) One of the cord blood bankers, this Los Angeles company is involved in the collection, testing, processing, and preservation of the blood from umbilical cords for use in future stem cell therapy. They own the Cord Partners umbilical cord blood banking company. They have recently generated negative earnings. The price to earnings ratio is 2.0.

For a free downloadable Excel database of cord blood and stem cell stocks, go to WallStreetNewsNetwork.com.

Disclosure: Author didn't own any of the above at the time the article was written.

By Stockerblog.com

Top Cord Blood Stocks

Recently, a doctor who was diagnosed with leukemia was saved with a cord blood transplant. The doctor was an obstetrician who was unable to find a matching bone marrow donor.

Cord blood comes from the umbilical cords of babies, and contains a large amount of hematopoietic stem cells. Specialized cord blood banks store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. The cord blood of a baby is preserved in the event it may be needed at some point in the future for treatment of possible cancer or genetic disease of the child or the child's siblings. Numerous diseases have been treated with cord blood. Information on cord blood and how it is collected, stored, and used, is available at CordBloodStocks.com.

Investors have a few options when investing in the cord blood industry. They can own the stocks of the cord blood banks, they can own the companies that use cord blood to develop cures, or they can own companies that produce extraction and storage products. WallStreetNewsNetwork.com has come up with a list of 20 companies involved in the cord blood field.

One example is PerkinElmer, Inc. (PKI), which owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and develop other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock trades at 32 times trailing earnings and sports a yield of 0.6%.

Perkinelmer, Inc - Stock Price and Volume | FindTheBest

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a trailing price to earnings ratio of 21 and pays a generous yield of 2.8%.

Baxter International Inc - Stock Price and Volume | FindTheBest

Celgene (CELG) is a New Jersey company that is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The stock has a trailing PE of 28.

Celgene Corporation - Stock Price and Volume | FindTheBest

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a trailing PE of 20 and carries a yield of 2.0%.

Amgen Inc - Stock Price and Volume | FindTheBest

For a free list of cord blood and stem cell stocks, which can be downloaded, updated, and sorted, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Cord Blood May Have Saved a Baby from Brain Damage: Top Cord Blood Stocks

A baby who had a stroke in utero, was treated with her own cord blood at Duke University. The cord blood had been stored from birth by a private cord blood bank. The director of the pediatric program at Duke believes that the cord blood cells help decrease inflammation in the section of the brain that was affected by stroke.

Cord blood is blood that comes from the umbilical cords of babies, and contains a significant amount of hematopoietic stem cells. Specialized cord blood banks store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Cord blood of a baby is preserved in the event it may be needed at some point in the future for treatment of possible cancer or genetic disease of the child or the child's siblings. Numerous diseases have been treated with cord blood. Information on cord blood and how it is collected, stored, and used, is available at CordBloodStocks.com.

Investors have a few options when investing in the cord blood industry. They can own the stocks of the cord blood banks, they can own the companies that use cord blood to develop cures, or they can own companies that produce extraction and storage products. WallStreetNewsNetwork.com has come up with a list of 20 companies involved in the cord blood field.

One example is PerkinElmer, Inc. (PKI), which owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock trades at 30 times earnings and pays a small yield of 0.6%.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a price to earnings ratio of 18 and sports a generous yield of 2.9%.

Celgene (CELG) is a New Jersey company that is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The stock has a PE of 46.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a forward PE of 19 and carries a decent yield of 2.0%.

For a free list of cord blood and stem cell stocks, which can be downloaded, updated, and sorted, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Top Stem Cells Stocks

There hasn't been much debate in the press recently about stem cells, however, there has been plenty of news.  For example, a mini-kidney was grown from stem cells by scientists. Researchers have now found a way to grow aged brain cells from stem cells. And finally, Plantar Fasciitis is now being treated with stem cells.

Extensive stem cell research is being done relating to the treatment of cancer, Parkinson's disease, and multiple sclerosis. Due to all the controversy about embryonic stem cells,  alternative sources are being studied, such a teeth and umbilical cord blood.

Several companies are involved in some aspect of stem cells and stem cell research. WallStreetNewsNetwork.com has turned up over a dozen stem cell stocks, and over half a dozen of which are generating profits.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with a $24.6 billion market cap that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 71 and a forward PE of 37. Earnings for the latest quarter were up 1.7%% on a 36.1% boost in revenues.

Integra Lifesciences Holdings (IART) is a New Jersey based company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The company recently generated a 59 cent loss per share on a 1.5% increase in sales. It has a market cap of $1.34 billion.

Cellgene (CELG) is a $69.6 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. They have a patent on placental stem cell recovery. The stock sports a PE ratio of 49 and a forward PE of 23. Quarterly earnings were down 12.2%% on an 18%% revenue increase.

For a free list of twenty stocks involved in stem cell research, along with some cord blood stocks, which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Stem Cells Developed from Blood: Top Stem Cell Companies

Stem cells therapies are currently used in bone marrow transplants that are used to treat leukemia, and scientists believe in the future, they can be used to treat cancer, Parkinson's disease, and multiple sclerosis. Researchers at the at the University of Cambridge have developed a way of producing stem cells with blood. The research was published in the Stem Cells: Translational Medicine journal. With all the controversy about embryonic stem cells, scientists are looking for alternative sources, such a teeth and umbilical cord blood.

Several companies are involved in some aspect of stem cells and stem cell research. WallStreetNewsNetwork.com has turned up over a dozen stem cell stocks, and over half a dozen of which are generating profits.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $18.7 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 85 and a forward PE of 42.6. Earnings for the latest quarter were up an incredible 40.6%% on a 44.2% boost in revenues.

Integra Lifesciences Holdings (IART) is a New Jersey based company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 33 times current earnings, and 12 times forward earnings. However, earnings for the latest quarter were up a strong 17.5% on a 3.9% rise in sales.

Cellgene (CELG) is a $29.8 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 22 and a forward PE of 14. Quarterly earnings were up 13.7%% on a 13.6%% revenue increase.

For a free list of twenty stocks involved in stem cell research, along with some cord blood stocks, which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Cord Blood May Treat Strokes and Spinal Cord Injuries

Salk Institute for Biological Studies researchers have discovered the use of a single protein called transcription factor-to convert cord blood cells may be helpful in treating spinal cord injuries, strokes, and other neurological disorders. Other research has shown that umbilical cord blood may be useful in treating leukemia. Several companies, both large and small, are involved in the cord blood industry, and Richard Branson has even invested in the cord blood business.

Cord blood is blood that comes from the umbilical cords of babies, and contains a significant amount of hematopoietic stem cells. Specialized cord blood banks store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Cord blood of a baby is preserved in the event it may be needed at some point in the future for treatment of the cancer or genetic disease of the child or the child's siblings. Many diseases have been treated with cord blood. Information on cord blood and how it is collected, stored, and used, is available at CordBloodStocks.com.

Investors have two options when investing in this industry. They can own the stocks of the cord blood banks or own the companies that use cord blood to develop cures and produce extraction and storage products. WallStreetNewsNetwork.com has come up with a list of 20 companies involved in the cord blood field. One example is PerkinElmer, Inc. (PKI), which owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock trades at 11 times forward earnings and pays a decent yield of 1.1%.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a forward price to earnings ratio of 11.4 and sports a yield of 2.4%.

Celgene (CELG) is a New Jersey company that is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The stock has a forward PE of 12.3.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a forward PE of 11.6 and carries a yield of 1.9%.

For a free list of cord blood and stem cell stocks, which can be downloaded, updated, and sorted, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Stem Cell Stocks

On Sunday evening, 60 Minutes broadcast an extensive report on stem cell scams. It reported on companies around the world that make outrageous claims with regards to the treatment and cures that stem cells can provide. Numerous people who have incurable diseases are desperately looking for cures, and are being taking advantage of by charlatans purporting to solve all their medical issues.

However, stem cells are being used currently for medical treatments. Look at bone marrow transplants that are used to treat leukemia utilizing adult stem cells. Scientists are actively looking at stem cells to treat diseases such as cancer, Parkinson's disease, and spinal cord injuries.

There are actually many publicly traded companies involved in stem cell research. WallStreetNewsNetwork.com has turned up over 20 stem cell stocks, half of which are currently profitable.

Integra Lifesciences Holdings (IART) is a New Jersey based company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 17 times current earnings, and 7.5 times forward earnings. However, earnings for the latest quarter were down 31.8%.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $13.7 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 92 and a forward PE of 45. Earnings for the latest quarter were up an amazing 135.2% on a 44% rise in revenues.

Cellgene (CELG) is a $29.8 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 28 and a forward PE of 15. Quarterly earnings were up 32.7% on a 37% revenue increase.

For a free list of over twenty stem cell stocks which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Many Cord Blood Companies Experiencing Double Digit Growth

A report called 'Capitalizing on Opportunities in Cord Blood Industry Growth' was just released by MarketResearch.com, which describes how a certain sector of blood banks are experiencing a very fast growth rate, ranging from 17% per year to 25% per year. The 201 page report is available for download for $3,995. This industry has got the attention of billionaires, such as Richard Branson, of Virgin Records and Virgin Atlantic Airways fame. He created Virgin Health, a cord blood bank.

So what is cord blood? Cord blood is blood that comes from the umbilical cords of babies, and contains a significant amount of hematopoietic stem cells. Specialized cord blood banks store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Cord blood of a baby is preserved in the event it may be needed at some point in the future for treatment of the cancer or genetic disease of the child or the child's siblings. Many diseases have been treated with cord blood. Information on cord blood and how it is collected, stored, and used, is available at CordBloodStocks.com.

Investors have two options when investing in this industry. They can own the stocks of the cord blood banks or own the companies that use cord blood to develop cures and produce extraction and storage products. One that falls into the second category is PerkinElmer, Inc. (PKI), which owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock trades at 10 times forward earnings and pays a decent yield of 1.5%.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a forward price to earnings ratio of 10 and sports a yield of 2.7%.

Celgene (CELG) is a New Jersey company that is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The stock has a forward PE of 14.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a forward PE of 10 and carries a yield of 2.0%.

China Cord Blood Corporation (CO) provides cord blood collection, and stem cell storage services. The company is based in Beijing, China. The stock trades at 9 times earnings.

For a free list of cord blood and stem cell stocks, which can be downloaded, updated, and sorted, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

U of Colorado Opens Cord Blood Bank: What About Cord Blood Stocks

University of Colorado recently opened a public cord blood bank, funded by the federal government. Donations are accepted from almost anyone and the cord blood is available to those in need.

Cord blood is blood that comes from the umbilical cords of babies, and contains a significant amount of hematopoietic stem cells. Specialized cord blood banks, both private and public, are available to store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Parents often have their baby's cord blood preserved in the event it may be needed at some point in the future for treatment of their child's or the child's sibling's cancer or genetic disease. Numerous diseases have been treated with cord blood. For a lot more detail on cord blood and how it is collected, stored, and used, go to CordBloodStocks.com.

The cord blood industry continues to grow. Even Richard Branson, of Virgin Records and Virgin Atlantic Airways fame, set up Virgin Health, a cord blood bank. Investors have a two-pronged approach to this investment industry: owning the stocks of the cord blood banks or owning the companies that use cord blood to develop cures.

PerkinElmer, Inc. (PKI) owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock trades at 12 times forward earnings and pays a yield of 1.3%.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a forward price to earnings ratio of 12 and pays a yield of 2.3%.

Celgene (CELG) is a New Jersey company that is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The forward PE is 14, but does not pay a dividend.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a forward PE of 10 and sports a yield of 2.1%.

China Cord Blood Corporation (CO) provides cord blood collection, and stem cell storage services. The company is based in Beijing, China. The stock does not pay a dividend but trades at 12 times earnings.

For a free list of cord blood and stem cell stocks, which can be downloaded, updated, and sorted, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Stem Cell Funding Ban Reversed: What About the Stocks?

Last week was a busy week for stem cells. The suspension of Federal funding for stem cell research has just been overturned by a United States Appeals Court. The two to one ruling last week said that the law against Federal funding was ambiguous. In addition, Dr. Paul Sharpe spoke at the First International Conference on Dental and Craniofacial Stem Cells in New York last week. He discussed the use of regenerative dentistry to regrow teeth with dental stem cells.

Research has been continuing into the use of stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions. Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. There are several publicly traded companies in the stem cell field, according to the free list of stem cell stocks at WallStreetNewsNetwork.com.

For example, Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $8.9 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a price to earnings ratio of 93 and a forward PE of 32.

Cellgene (CELG) is a $27.4 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 31 and a forward PE of 14.

Integra Lifesciences Holdings (IART) is a New Jersey based $1.5 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 24 times current earnings, and 16 times forward earnings.

For a free list of over a dozen stem cell stocks which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

Stem Cell Stocks Are Growing

According to the latest Journal of the Congress of Neurological Surgeons Research, Neurosurgery, bone marrow stem cells derived from a patient's own bone marrow were safely used in pediatric patients with severe traumatic brain injury, according to results of a Phase I clinical trial at The University of Texas Health Science Center at Houston.

Research has been continuing into the utilization of stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions. Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. WallStreetNewsNetwork.com just updated its free downloadable list of over ten stem cell stocks. Can one of these provide a cure for your portfolio?

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with an $8.9 billion market capitalization that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The company licenses porcine embryonic stem cells for transgenic animals. The stock has a PE of 94 and a forward PE of 33.

Cellgene (CELG) is a $24.7 billion market cap company involved in the discovery and production of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the company's main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received a patent on placental stem cell recovery. The stock sports a PE ratio of 28 and a forward PE of 13.

Integra Lifesciences Holdings (IART) is a New Jersey based $1 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The stock trades at 22 times earnings, and 14.5 times forward earnings.

For a database of over a dozen stem cell stocks which you can download, sort, and update, go to WallStreetNewsNetwork.com.

Disclosure: Author did not own any of the above at the time the article was written.

By Stockerblog.com

First US Trial of Embryonic Stem Cells in Humans

The Food and Drug Administration has given the go ahead to Geron (GERN) to use human embryonic stem cells in human patients. The trial study will be sued to treat patients with spinal injuries. Previous studies have shown that paralyzed rats have achieved some movement after treatment.

Geron, which has expended $170 million on stem cell research, was up about 6% today on the news. The stock generated a quarterly loss of 73 cents for the latest reported quarter, however, revenues were up 447% during the same time frame. The company will report earnings on October 28. This debt free company has $1.19 in cash per share.

Research has been continuing to utilize stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, macular degeneration, and many other medical conditions. Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. WallStreetNewsNetwork.com developed a downloadable list of over ten stem cell stocks. Hopefully your portfolio will receive a cure with one of these companies. Here is a list of a few opportunities.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with a $6 billion market cap that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The stock has a PE of 20 and a forward PE of 28.

Cellgene (CELG) is a $26 billion market cap company involved in the discovery and production, of therapies designed to treat cancer and immune-inflammatory-related diseases. One of the main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. The company also received patent on placental stem cell recovery. The stock sports a PE of 31 and a forward PE of 17.

Integra LifeSciences Holdings (IART) is a New Jersey based $1 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. The P/E is 19, and the forward PE is 13.

For an Excel database of over ten stem cell stocks which you can download, sort, and change, go to WallStreetNewsNetwork.com.

Disclosure: Author does not own any of the above at the time the article was written.

By Stockerblog.com

Top Cord Blood Stocks

The University of South Florida Department of Neurosurgery and Brain Repair just published the results of their research showing that after stroke-like damage, human umbilical cord blood cells protect astrocytes (animal cells) from cell death when deprived of oxygen.

Cord blood is blood that comes from umbilical cords, and contains a significant amount of hematopoietic stem cells. Specialized cord blood banks are available to store this blood. Cord blood stem cells are considered far superior to stem cells from bone marrow. Parents often have their newborn's cord blood preserved in the event it may be needed at some point in the future for treatment of their child's or the child's sibling's cancer or genetic disease. Numerous diseases have been treated with cord blood. For a lot more detail on cord blood and how it is collected, stored, and used, go to CordBloodStocks.com.

The cord blood industry is a fast growing industry, and includes the likes of Richard Branson, of Virgin Records and Virgin Atlantic Airways fame, who set up Virgin Health, a cord blood bank.

Investors have the option of owning the cord blood banks or the companies that use cord blood to develop cures (or both). Here are some stocks that participate in the cord blood business. Be aware that some of these companies have low market caps and are very speculative.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to disburse the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a PE ratio of 17 and pays a yield of 2.6%.

PerkinElmer, Inc. (PKI) owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock has a PE of 19 and a yield of 1.4%.

Celgene (CELG) This New Jersey company is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The P/E is 27.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a PE of 11.

China Cord Blood Corporation (CO) provides cord blood collection, and stem cell storage services.The company is based in Beijing, China. The stock has a PE of 40 and a forward PE of 20.

The following stocks are extremely low cap stock and should therefore be considered extremely speculative.

Cryo-Cell International (CCEL.OB) This is a Florida based cord blood stem cell bank, specializing in the family market. The stock has a PE ratio of 10.

ThermoGenesis (KOOL) This California company designs, makes, and sells automated blood processing systems for the manufacture, preservation, and delivery of cell therapies. They are involved in a joint venture with GE Healthcare, a unit of General Electric Company (GE) to distribute the AXP[TM] AutoXpress Platform, a closed and automated system for harvesting mononuclear cells from cord blood. They have recently generated negative earnings.

Cord Blood America Inc. (CBAI.OB) One of the cord blood bankers, this Los Angeles company is involved in the collection, testing, processing, and preservation of the blood from umbilical cords for use in future stem cell therapy. They own the Cord Partners umbilical cord blood banking company. They have recently generated negative earnings.

For a free list of cord blood and stem cell stocks, which can be downloaded and sorted, go to WallStreetNewsNetwork.com.

Author does not own any of the above.

By Stockerblog.com

Top Stem Cell Stocks

In March of last year, President Barack Obama signed an executive order to eliminate a ban on federal funding for embryonic stem-cell research. This policy change should cause a substantial increase in research into stem cell therapy. Research has been continuing to utilize stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions.

Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. WallStreetNewsNetwork.com just came up with a downloadable list of over ten stem cell stocks. Maybe one of these will provide a cure for your portfolio.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with a $4.7 billion market cap that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The stock has a PE of 15.9 and a forward PE of 21.6.

Cellgene (CELG) is a $24.3 billion market cap company involved in the discovery and production, of therapies designed to treat cancer and immune-inflammatory-related diseases. One of their main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received patent on placental stem cell recovery. The stock sports a PE of 29 and a forward PE of 16.5.

Integra Lifesciences Holdings (IART) is a New Jersey based $1 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. Their P/E is 17.8, and the forward PE is 11.5.

For an Excel database of over ten stem cell stocks which you can download, sort, and change, go to WallStreetNewsNetwork.com.

Author does not own any of the above.

By Stockerblog.com

Cord Blood Stocks

Cord blood has been in the news a lot recently. A Florida hospital is waiving the fee for the donation of cord blood. Five cord blood transfer centers in Spain have joined a study for the treatment of lymphoma and leukemia. And a cord blood bank in Texas has added Midland Memorial Hospital to is collection network.

Cord blood is blood that comes from umbilical cords, and contains an extensive amount of hematopoietic stem cells. The blood is kept in depositories called blood banks. Cord blood stem cells are considered far superior to stem cells from bone marrow. Many parents have their newborn's cord blood preserved in the event it may be needed at some point in the future for treatment of their child's or the child's sibling's cancer or genetic disease. Over 75 diseases have been treated with cord blood. For a lot more detail on cord blood and how it is collected, stored, and used, go to CordBloodStocks.com.

Even Richard Branson, of Virgin Records and Virgin Atlantic Airways fame, is in the cord blood business. He set up Virgin Health, a cord blood bank.

There are a couple ways to invest in the cord blood industry, the cord blood banks and the companies that use cord blood to develop cures. Here are several stocks that participate in the cord blood business. Please be aware that many of these companies have low market caps and are extremely speculative.

Cord Blood America Inc. (CBAI.OB) One of the cord blood bankers, this Los Angeles company is involved in the collection, testing, processing, and preservation of the blood from umbilical cords for use in future stem cell therapy. They own the Cord Partners umbilical cord blood banking company. They have recently generated negative earnings. This is an extremely low cap stock and should therefore be considered extremely speculative.

ThermoGenesis (KOOL) This California company designs, makes, and sells automated blood processing systems for the manufacture, preservation, and delivery of cell therapies. They are involved in a joint venture with GE Healthcare, a unit of General Electric Company (GE) to distribute the AXP(TM) AutoXpress Platform, a closed and automated system for harvesting mononuclear cells from cord blood. They have a price sales ratio of 1.4. They have recently generated negative earnings. This is an extremely low cap stock and should therefore be considered extremely speculative.

Cryo-Cell International (CCEL.OB) This is a Florida based cord blood stem cell bank, specializing in the family market. The stock has a PE ratio of 665. This is an extremely low cap stock and should therefore be considered extremely speculative.

PerkinElmer, Inc. (PKI) owns ViaCell, a Cambridge, Massachusetts company which sells ViaCord, a product which is used to preserve baby's umbilical cord blood. They also research and other therapeutic uses of umbilical cord blood-derived and adult-derived stem cells. The stock has a PE of 17 and a yield of 1.7%.

Celgene (CELG) This New Jersey company is involved in the discovery, production, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. They own LifeBank USA, a cord blood bank. The P/E is 74.

Baxter International Inc. (BAX) makes blood collection bags for umbilical cord blood and develop adult stem-cell therapies. They also own a patent for assembling and methods to process cord blood in a sterile fashion to avoid exposure to bacterial contamination and to meter the introduction of cryopreservation solution into cord blood at a desired rate, thereby avoiding damage or trauma to the cord blood cells. The stock has a PE ratio of 14 and pays a yield of 2.1%.

Amgen Inc. (AMGN) is also funding research into cord blood extraction, preservation, and storage. The stock has a PE of 13.

For a free downloadable Excel database of cord blood and stem cell stocks, go to WallStreetNewsNetwork.com.

Author does not own any of the above.